Concepedia

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen

Esteban Ribera, Carlos Azuaje, Rosa María López, M. Medina Díaz, María Feijoo-Cid, Leonor Pou, Manuel Crespo, Adrián Curran, I Ocaña, Albert Pahissa

AIDS · 2006 · 48 citations · 29 references

DOI

Abstract

The combination of ATV and LPV/RTV provided high plasma concentrations of both PI, which seemed to be appropriate for patients with multiple prior therapeutic failures, yielding good tolerability and substantial antiviral efficacy.

References

29

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Adriano Lazzarin, Bonaventura Clotet, David A. Cooper et al. · New England Journal of Medicine · 2003 · 651 citations · Full text

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

Kathleen Squires, Adriano Lazzarin, Jos M. Gatell et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 299 citations

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

Margaret Johnson, Beatriz Grinsztejn, Claudia Rodríguez et al. · AIDS · 2005 · 249 citations

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

Robert L. Murphy, Scott Brun, Charles B. Hicks et al. · AIDS · 2001 · 238 citations

Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects

Ian Sanne, Peter J. Piliero, Kathleen Squires et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2003 · 223 citations